New Vaccine Post-Introduction Evaluation - libdoc.who.int - World ...

More documents

Recommendations

Info

Abbreviation GEN 61. Are follow-up visits conducted at sites with inadequate performance and continuing problems? Central/Regional/District Questionnaire Yes No DIST GEN 62. Have you received a supervisory visit? If yes, when and by whom? ADVERSE EVENTS FOLLOWING IMMUNIZATION (AEFI) 63. Do you have a system and written protocol for monitoring and reporting AEFIs for all vaccines? Please describe the procedure. Yes No When _ ______________________________ By whom ____________________________ Ask to see a copy of the visit report. Yes No If no, why not _ ________________________ Ask for a copy of the AEFI protocol and reporting form. . GEN GEN GEN GEN GEN GEN 64. Do you have a crisis plan in place to manage AEFIs? Please describe. 65. Did you make any changes to the AEFI protocol specifically for the new vaccine? 66. Have you had any reported AEFIs for the new vaccine or another vaccine since the new vaccine was introduced? Note: Verify using AEFI logbook/registry if available. ADVOCACY & COMMUNICATION 67. Did you have an official launch ceremony at the time of the new vaccine introduction? Note: If yes, what did it involve, was it successful, did it get much media coverage, how long before the introduction of the new vaccine did it take place? 68. Did you use any media outlets to promote the new vaccine and inform/educate the community about the vaccine? Note: Please ask for copies of any materials. 69. Did you prepare or distribute any health education material for the community on the new vaccine? If yes, what were they? Who were the target audiences? When and how were they distributed? Note: Please ask for copies of any materials. Yes No Don’t know If yes, How many for the new vaccine____________ How many for a traditional vaccine (specify) _ ____________________________________ What were the AEFIs___________________ How were they handled? _ _______________ Yes No Don’t know If yes, describe ________________________ If no, why not? _ _______________________ Check all that apply: Radio Television Community groups Town crier Celebrity Government officials Other (specify) Main messages _ ______________________ Check all that apply: Posters Brochures Flyers Clothing (t-shirts, hats etc.) Other (specify) Target audiences _ _____________________ Main messages _ ______________________ WHO/IVB/10.03 31
Abbreviation CENT CENT CENT C&R SUSTAINABILITY 70. Is there a budget line for vaccine purchases in the national budget? 71. How are traditional EPI vaccines financed? Note: List all sources that pay for the vaccine. 72. How is the new vaccine paid for? Note: List all sources that pay for the vaccine. 73. Do you plan to introduce any more new vaccines in the future? If yes, which one(s) and when? Note: If they say no, this is an opportunity to mention new vaccines, such as pneumococcal vaccine, rotavirus vaccine and HPV, that probably will be available in the future. Central/Regional/District Questionnaire C&R C&R C&R GEN GEN SURVEILLANCE 74. Do you have surveillance for the diseases which the new vaccine will prevent? Please describe. Note: Include the number of sites, date started. Ask for a copy of the surveillance data/bulletin. 75. Have there been any problems with the surveillance? IMPACT ASSESSMENT 76. Are you conducting, or do you plan to conduct, a vaccine impact assessment, i.e. a study to determine if the new vaccine is reducing disease burden? GENERAL IMPRESSIONS 77. How well was the new vaccine accepted? If there were any problems, please comment for each group. Note: Was it considered to be a safe and effective, and needed vaccine? 78. Were there financial implications in introducing the new vaccine for each of the following areas? Yes No Don’t know If yes, describe_ _______________________ Yes No Don’t know If yes, give details______________________ If no, why not? _ _______________________ New vaccine well accepted Health-care workers Yes No Professional societies Yes No Community/public Yes No Government Yes No Media Yes No On what is your answer based? ___________ Discuss any problems___________________ Ask about the financial implications of each of the following: Cold chain Yes No If yes, specify:_________________________ Vaccine transport Yes No If yes, specify:_________________________ Wastage Yes No If yes, specify:_________________________ Communication materials/ media Yes No If yes, specify:_________________________ Training Yes No If yes, specify:_________________________ Other costs? Yes No If yes, specify:_________________________ 32 New Vaccine Post-Introduction Evaluation (PIE) Tool
Page 1 and 2: WHO/IVB/10.03 ORIGINAL: ENGLISH New
Page 3 and 4: The Department of Immunization, Vac
Page 5 and 6: 5. Appendices......................
Page 7 and 8: Acknowledgements This Post-Introduc
Page 9 and 10: viii
Page 11 and 12: 1.3 What is a PIE? A PIE is a post-
Page 13 and 14: Table 2: Example of data and docume
Page 15 and 16: When in the field, teams should ide
Page 17 and 18: 2. Evaluation areas Data are collec
Page 19 and 20: Coverage The primary indicator of v
Page 21 and 22: 2.3 Cold-chain management Some vacc
Page 23 and 24: 2.5 Monitoring and supervision A fi
Page 25 and 26: 2.8 Vaccine wastage Wastage, partic
Page 27 and 28: 3. Data synthesis and reporting A l
Page 29 and 30: 4. Reference documents / websites
Page 31 and 32: Appendix 2: Questionnaires Layout a
Page 33 and 34: Appendix 2.1: Questionnaire — cen
Page 35 and 36: Abbreviation ROTA GEN 11. Is there
Page 37 and 38: Abbreviation CENT/REG GEN GEN GEN G
Page 39: Abbreviation GEN GEN GEN PENTA PENT
Page 43 and 44: Abbreviation GEN GEN GEN For vaccin
Page 45 and 46: Abbreviation GEN GEN GEN 1. Were yo
Page 47 and 48: Abbreviation GEN GEN 15. Have immun
Page 49 and 50: Abbreviation GEN GEN WASTE MANAGEME
Page 51 and 52: Abbreviation ROTA ROTA PENTA GEN GE
Page 53 and 54: Abbreviation GEN 64. Are appropriat
Page 55 and 56: Appendix 2.3: Questionnaire — mot
Page 57 and 58: Appendix 4: Summary spreadsheet Sum
Page 59 and 60: Level Question Central Regional Reg
Page 67 and 68: Appendix 5: Summary spreadsheet Sum
Page 69 and 70: Advocacy, Communication and Accepta
Page 71 and 72: Appendix 6: Common problems and sol
Page 73 and 74: Scenario Over- or under-stock of va
Page 75 and 76: 66 New Vaccine Post-Introduction Ev

New Vaccine Post-Introduction Evaluation - libdoc.who.int - World ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?